Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1189 results
March 2015
-
Media ReleaseNovartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
-
Media ReleaseFDA approves first biosimilar ZarxioTM (filgrastim-sndz) from SandozSandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Media ReleaseNovartis announces completion of transactions with GSKCompletes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
-
Media ReleaseNovartis gibt Abschluss von Transaktionen mit GSK bekanntMit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
-
Media ReleaseNovartis annonce la conclusion des transactions avec GSKConclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
February 2015
-
Media ReleasePositive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degenerationPhase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Novartis Board of DirectorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administrationLes actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
-
Media ReleaseAktionäre genehmigen alle Anträge des Verwaltungsrats von NovartisAktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
-
Media ReleaseNovartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinibIf approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
-
Media ReleaseNovartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myelomaFarydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority reviewDecision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
Pagination
- ‹ Previous page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- › Next page